<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01551940</url>
  </required_header>
  <id_info>
    <org_study_id>2010.607/11</org_study_id>
    <nct_id>NCT01551940</nct_id>
  </id_info>
  <brief_title>Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea</brief_title>
  <acronym>ALS-TOX</acronym>
  <official_title>Evaluation of Efficacy of Botulinum Toxin Type A in the Treatment of Sialorrhea in the Patient Affected by Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the decrease of the secretion of saliva in patients with amyotrophic lateral
      sclerosis by a local ultrasound-guided bilateral injection of botulinum toxin type A in
      parotids and submandibular glands. The investigators want to demonstrate 1 month after the
      injection, by a multicenter French randomized double blind study, an improvement of at least
      25 % of the functional embarrassment due to saliva, estimated with a visual analogue scale, a
      decrease of the quantity of saliva and a decrease of the embarrassment for the main
      caregiver.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient will benefit from an ultrasound guided injection of botulinum toxin A (Botox®) or
      placebo (NaCl 0.9 %) and will be followed up in consultation at 4, 12, 16 (if reinjection)
      and 24 weeks. He will be contacted by telephone in 2 and in 8 weeks (percentage of decrease
      of functional embarrassment, percentage of decrease of salivary secretion rate). He can be
      able to benefit in the open label phase of a botulinum toxin type A injection at the 12-week
      follow up if he estimates that first injection was not effective or if the efficiency of the
      first injection began to become blurred. After the 6 months of the study, the patient will
      benefit again from the usual follow-up as advised by the French consensus conference in
      November, 2005.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of the functional embarrassment provoked by sialorrhea</measure>
    <time_frame>1 month after the injection</time_frame>
    <description>Demonstrate after the injection of botulinum toxin type A an improvement of at least 25 % of the functional embarrassment provoked by sialorrhea in the ALS patient, evaluated with a horizontal visual analogue scale (VAS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver</measure>
    <time_frame>1 month after the injection</time_frame>
    <description>Demonstrate, one month after the injection of botulinum toxin type A, a decrease of the salivary secretion rate and a decrease of the embarrassment for the main caregiver by a horizontal visual analogue scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the value of the hypersalivation item in ALSFRS-R scale</measure>
    <time_frame>1 month after the injection</time_frame>
    <description>Demonstrate, one month after the injection of botulinum toxin type A, an improvement of the value of the hypersalivation item in ALSFRS-R scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of the score of severity and frequency of the drooling rating scale</measure>
    <time_frame>1 month after the injection</time_frame>
    <description>Demonstrate, one month after the injection of botulinum toxin type A, a decrease of the score of severity and frequency of the drooling rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of the cotton roll weight</measure>
    <time_frame>1 month after the injection</time_frame>
    <description>Demonstrate, one month after the injection of botulinum toxin type A, a decrease of the cotton roll weight.
Cotton rolls weight: production and quantity of saliva are verified by placing dental cotton rolls during 3 minutes in the mouth of the patient and by comparing the weight of rolls dry and soaked with saliva.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of the number of paper handkerchiefs used</measure>
    <time_frame>1 month after the injection</time_frame>
    <description>Demonstrate, one month after the injection of botulinum toxin type A, a decrease of the number of paper handkerchiefs used. We ask the patient to count the number of handkerchiefs used a day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification of the speech evaluation</measure>
    <time_frame>1 month after the injection</time_frame>
    <description>Demonstrate, one month after the injection of botulinum toxin typeA, a modification of the speech evaluation (evaluation realized by speech evaluator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the quality of life</measure>
    <time_frame>1 month after the injection</time_frame>
    <description>Demonstrate, one month after the injection of botulinum toxin type A, an improvement of the quality of life. Scale to estimate quality of life (ALSAQ-40), usually used with the patients affected by ALS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of patient cohort after the first injection</measure>
    <time_frame>6 months after the injection</time_frame>
    <description>Describe cohort after the first injection: evolution of scores for every patient among Day0 and Month1, delay of appearance of the efficiency, the duration of effect of the treatment, the side effects, the modification of the consistency of the saliva and the possible necessity for re-injecting the patient at 3 months of follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Sialorrhea</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Botox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botox injection : 100 UI of botulinum toxin type A (Botox®) diluted in 2.2 ml of NaCl 0.9 %</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injection : NaCl 0.9 %</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox injection</intervention_name>
    <description>Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.</description>
    <arm_group_label>Botox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo injection</intervention_name>
    <description>A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Obtaining of a written consent after information

          -  Diagnosis of probable or certain ALS according to the El Escorial criteria of the
             World Federation and Neurology Committee on Neuromuscular Diseases

          -  Patient having a follow-up in an ALS center

          -  Sialorrhea with VAS functional embarrassment &gt; or equal at 50/100.

          -  Patient beneficiary of Social Security regime

        Exclusion Criteria:

          -  Evolving disease associated with predictable survival &lt; 1 month

          -  Patient having previously received an injection of botulinum toxin in the salivary
             glands

          -  Patient taking the other medical treatments for sialorrhea in the 7 days before the
             inclusion in the study (scopoderm, trihexyph'nidyle, atropine, ipatropium,
             amitriptyline, clomipramine, oxybutinine, diphenhydramine, beta-blockers)

          -  Patient having benefited from radiotherapy or from surgery on the salivary glands

          -  Behavioral problems, dementia or other psychiatric problems

          -  Myasthenia

          -  Known Pregnancy or absence of contraception recognized as effective, breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe VIAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre SLA, Groupement Hospitalier Est, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Département de Neurologie, Hôpital de l'Hôtel-Dieu, CHU d'Angers</name>
      <address>
        <city>Angers cedex 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre SLA, Groupement Hospitalier Est, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie Vastel, Hôpital Côte de Nacre, CHU de Caen</name>
      <address>
        <city>Caen cedex 9</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, Hôpital Gabriel Montpied, CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre SLA, Service de Neurologie A et pathologies du mouvement, Hôpital Roger Salengro, CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, Hôpital Dupuytren, CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, Hôpital de la Timone, CHU de Marseille</name>
      <address>
        <city>Marseille cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, Hôpital Central, CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Référence maladies Neuromusculaires, Service de Médecine Physique et Réadaptation, Hôpital de l'Archet 1, CHU de Nice</name>
      <address>
        <city>Nice cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fédération des Maladies du Système Nerveux, Groupement Hospitalier Pitié Salpêtrière, AP-HP</name>
      <address>
        <city>Paris cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie, CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne cedex 2</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de Neurologie, Hôpital de Hautepierre, CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Explorations Fonctionelles Neuro-Musculaires, Hôpital Rangueil, CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <last_update_submitted>August 13, 2015</last_update_submitted>
  <last_update_submitted_qc>August 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sialorrhea</keyword>
  <keyword>Amyotrophic lateral sclerosis</keyword>
  <keyword>Botulinum toxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sialorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

